Cancer
Neoplasm of Uncertain Histogenesis
CI-CAN-00000034Explore in graph →
Non-malignant20,280 active trials259 approved drugs3,813 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00000034Explore in graph →
Clinical trials
91,351 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06196255 | Safety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM) | recruiting | Phase 1 / Phase 2 | 20 | Xuzhou Medical UniversityOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT05675813 | Genotype-guided Treatment in Newly Diagnosed PTCL(THEORY) | recruiting | Phase 1 / Phase 2 | 264 | Ruijin HospitalOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT05833763 | A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.(GOlDiLOX) | recruiting | Phase 2 | 42 | Australasian Leukaemia and Lymphoma GroupOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT04716686 | Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma | recruiting | Phase 2 | 83 | Shandong UniversityOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT05964569 | Feasibility of Individualized, Model-guided Optimization of Proton Beam Treatment Planning in Patients With Low Grade Glioma(INDIGO) | recruiting | Phase 2 | 120 | University Hospital HeidelbergOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT06190639 | A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC | recruiting | Phase 2 | 31 | Zhejiang Cancer HospitalOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT06088030 | Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer | recruiting | Phase 2 | 50 | Yang LiOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT06165900 | Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC | recruiting | Phase 2 | 136 | Shengjing HospitalOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT06061146 | Tislelizumab Plus Concurrent Chemoradiation in Older With ESCC(TCRTOE) | recruiting | Phase 2 | 136 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT04894370 | Combination of Spartalizumab, mDCF and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma(SPARTANA) | recruiting | Phase 2 | 34 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Dec 22, 2023 | clinicaltrials |
| NCT06168786 | Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC | recruiting | Phase 2 | 40 | Huazhong University of Science and TechnologyOTHER | 1 | Dec 21, 2023 | clinicaltrials |
| NCT06001086 | A Phase II Clinical Study of Treatment With Disitamb Vedotin Plus Pyrotinib in HER2-positive Early Breast Cancer | recruiting | Phase 2 | 70 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT06176729 | Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients | recruiting | Phase 2 | 30 | Yan Zhang, MDOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT06177925 | A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC | recruiting | Phase 2 | 62 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT05427383 | KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy | recruiting | Phase 2 / Phase 3 | 286 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | Dec 19, 2023 | clinicaltrials |
| NCT06173986 | Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer | recruiting | Phase 1 / Phase 2 | 50 | Shanghai Chest HospitalOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT06155383 | Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma. | recruiting | Phase 2 | 90 | RemeGen Co., Ltd.INDUSTRY | 1 | Dec 14, 2023 | clinicaltrials |
| NCT06170710 | Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC | recruiting | Phase 2 | 173 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 14, 2023 | clinicaltrials |
| NCT04242017 | Long-term Better Than Short-term ADT With Salvage RT(LOBSTER) | recruiting | Phase 2 / Phase 3 | 394 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT06159478 | Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume)(Perfume) | recruiting | Phase 2 | 32 | National Cancer Center, JapanOTHER_GOV | 1 | Dec 13, 2023 | clinicaltrials |
| NCT06158269 | DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma | recruiting | Phase 2 | 40 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT05788679 | A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS | recruiting | Phase 2 | 200 | Karolinska University HospitalOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT04729543 | MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer(MC2TCR) | recruiting | Phase 1 / Phase 2 | 20 | Erasmus Medical CenterOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT05694312 | Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL | recruiting | Phase 2 | 45 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Dec 1, 2023 | clinicaltrials |
| NCT04214366 | Adenoid Cystic Carcinoma and Carbon Ion Only Irradiation(ACCO) | recruiting | Phase 2 | 314 | Heidelberg UniversityOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT06147570 | A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer | recruiting | Phase 2 | 62 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 27, 2023 | clinicaltrials |
| NCT05451784 | Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS(TILS001) | recruiting | Phase 1 / Phase 2 | 20 | Fundacio Clinic BarcelonaOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT02290145 | Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage | recruiting | Phase 2 | 48 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT05069857 | Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients | recruiting | Phase 2 | 46 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT05125055 | Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC | recruiting | Phase 2 / Phase 3 | 80 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT05961124 | Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer | recruiting | Phase 2 | 40 | Sunnybrook Health Sciences CentreOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT06132711 | Safety and Efficacy of APRIL-BAFF-Bicephali CAR-T in Relapsed, Refractory Multiple Myeloma(CAR-T) | recruiting | Phase 1 / Phase 2 | 20 | Xuzhou Medical UniversityOTHER | 1 | Nov 15, 2023 | clinicaltrials |
| NCT06130332 | Neoadjuvant Tirellizumab Combined With Chemotherapy for Early Oral Squamous Cell Carcinoma(HNC-SYSU-004) | recruiting | Phase 2 | 40 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Nov 14, 2023 | clinicaltrials |
| NCT05344209 | Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer(LUNGVAC) | recruiting | Phase 2 | 138 | Vestre Viken Hospital TrustOTHER | 1 | Nov 9, 2023 | clinicaltrials |
| NCT06125652 | Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML) | recruiting | Phase 1 / Phase 2 | 20 | Xuzhou Medical UniversityOTHER | 1 | Nov 9, 2023 | clinicaltrials |
| NCT06121700 | Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer(Miracle-G) | recruiting | Phase 2 | 55 | Fudan UniversityOTHER | 1 | Nov 8, 2023 | clinicaltrials |
| NCT06122493 | Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 48 | Ruijin HospitalOTHER | 1 | Nov 8, 2023 | clinicaltrials |
| NCT05494060 | XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma(EXPLORING) | recruiting | Phase 2 | 80 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT06114225 | Pulmonary Resectable Osteosarcoma Treated by Metastasectomy and Pre-operative Immunotherapy and Stereotactic Body Radiotherapy (PROMIS): a Prospective Clinical Trial(PROMIS) | recruiting | Phase 2 | 43 | Ruijin HospitalOTHER | 1 | Nov 2, 2023 | clinicaltrials |
| NCT05849857 | Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries(MERLIN) | recruiting | Phase 2 | 80 | Oslo University HospitalOTHER | 2 | Nov 1, 2023 | clinicaltrials |
| NCT06074692 | PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA)(PRIMA) | recruiting | Phase 2 | 86 | Ruijin HospitalOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT05985109 | KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer | recruiting | Phase 2 | 98 | Peking University Cancer Hospital & InstituteOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT06099821 | KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade | recruiting | Phase 2 | 39 | Peking University Cancer Hospital & InstituteOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT05573802 | A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 36 | Hellenic Society of HematologyOTHER | 1 | Oct 24, 2023 | clinicaltrials |
| NCT05230680 | Azacitidine-CHOP for Patients With Nodal T-cell Lymphoma With T-follicular Helper Phenotype (ACANTUS) | recruiting | Phase 1 / Phase 2 | 41 | Won Seog KimOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT06092086 | Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC | recruiting | Phase 2 | 126 | Guangdong Association of Clinical TrialsOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT05260671 | Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN | recruiting | Phase 2 | 48 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Oct 18, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jan 9, 2024source: clinicaltrials